View in EDS

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

Saved in:
Bibliographic Details
Title: Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
Authors: Martin M; Instituto de Investigación Sanitaria Gregorio Marañón, Grupo Español de Investigación en Cáncer de Mama (GEICAM), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Universidad Complutense, Madrid, Spain. Electronic address: mmartin@geicam.org., Holmes FA; Texas Oncology, Houston, TX, USA., Ejlertsen B; Rigshospitalet, Copenhagen, Denmark., Delaloge S; Institut Gustave Roussy, Villejuif, France., Moy B; Massachusetts General Hospital Cancer Center, Boston, MA, USA., Iwata H; Aichi Cancer Center, Chikusa-ku, Nagoya, Japan., von Minckwitz G; Luisenkrankenhaus, German Breast Group Forschungs GmbH, Düsseldorf, Neulsenburg, Germany., Chia SKL; BC Cancer Agency, Vancouver, BC, Canada., Mansi J; Guy's and St Thomas' Hospital National Health Service Foundation Trust and Biomedical Research Centre, King's College, London, UK., Barrios CH; Pontifical Catholic University of Rio Grande do Sul School of Medicine, Porto Alegre, Brazil., Gnant M; Department of Surgery and Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria., Tomašević Z; Daily Chemotherapy Hospital, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia., Denduluri N; Virginia Cancer Specialists, Arlington, VA, USA., Šeparović R; University Hospital for Tumors, University Hospital Center 'Sestre milosrdnice', Zagreb, Croatia., Gokmen E; Ege University Faculty of Medicine, Izmir, Turkey., Bashford A; Auckland Hospital, Auckland, New Zealand., Ruiz Borrego M; Oncology Department, Hospital Universitario Virgen del Rocio, Seville, Spain., Kim SB; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Jakobsen EH; Department of Oncology, Lillebaelt Hospital, Vejle, Denmark., Ciceniene A; Oncology Institute of Vilnius University, Vilnius, Lithuania., Inoue K; Breast Oncology, Saitama Cancer Center, Kita-Adachi, Japan., Overkamp F; Oncologianova GmbH, Recklinghausen, Germany., Heijns JB; Department of Medical Oncology, Amphia Hospital, Breda, Netherlands., Armstrong AC; Department of Oncology, Christie Hospital Manchester, Manchester, UK., Link JS; Breastlink Medical Group Inc, Santa Ana, CA, USA., Joy AA; University of Alberta, Department of Oncology, Cross Cancer Institute, Edmonton, AB, Canada., Bryce R; Puma Biotechnology Inc, Los Angeles, CA, USA., Wong A; Puma Biotechnology Inc, Los Angeles, CA, USA., Moran S; Puma Biotechnology Inc, Los Angeles, CA, USA., Yao B; Puma Biotechnology Inc, Los Angeles, CA, USA., Xu F; Puma Biotechnology Inc, Los Angeles, CA, USA., Auerbach A; Puma Biotechnology Inc, Los Angeles, CA, USA., Buyse M; International Drug Development Institute, Louvain-la-Neuve, Belgium., Chan A; Breast Cancer Research Centre-Western Australia, Perth, WA, Australia; Curtin University, Perth, WA, Australia.
Corporate Authors: ExteNET Study Group
Source: The Lancet. Oncology [Lancet Oncol] 2017 Dec; Vol. 18 (12), pp. 1688-1700. Date of Electronic Publication: 2017 Nov 13.
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 29146401
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Martin+M%22">Martin M</searchLink>; Instituto de Investigación Sanitaria Gregorio Marañón, Grupo Español de Investigación en Cáncer de Mama (GEICAM), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Universidad Complutense, Madrid, Spain. Electronic address: mmartin@geicam.org.<br /><searchLink fieldCode="AU" term="%22Holmes+FA%22">Holmes FA</searchLink>; Texas Oncology, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Ejlertsen+B%22">Ejlertsen B</searchLink>; Rigshospitalet, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Delaloge+S%22">Delaloge S</searchLink>; Institut Gustave Roussy, Villejuif, France.<br /><searchLink fieldCode="AU" term="%22Moy+B%22">Moy B</searchLink>; Massachusetts General Hospital Cancer Center, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Iwata+H%22">Iwata H</searchLink>; Aichi Cancer Center, Chikusa-ku, Nagoya, Japan.<br /><searchLink fieldCode="AU" term="%22von+Minckwitz+G%22">von Minckwitz G</searchLink>; Luisenkrankenhaus, German Breast Group Forschungs GmbH, Düsseldorf, Neulsenburg, Germany.<br /><searchLink fieldCode="AU" term="%22Chia+SKL%22">Chia SKL</searchLink>; BC Cancer Agency, Vancouver, BC, Canada.<br /><searchLink fieldCode="AU" term="%22Mansi+J%22">Mansi J</searchLink>; Guy's and St Thomas' Hospital National Health Service Foundation Trust and Biomedical Research Centre, King's College, London, UK.<br /><searchLink fieldCode="AU" term="%22Barrios+CH%22">Barrios CH</searchLink>; Pontifical Catholic University of Rio Grande do Sul School of Medicine, Porto Alegre, Brazil.<br /><searchLink fieldCode="AU" term="%22Gnant+M%22">Gnant M</searchLink>; Department of Surgery and Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria.<br /><searchLink fieldCode="AU" term="%22Tomašević+Z%22">Tomašević Z</searchLink>; Daily Chemotherapy Hospital, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia.<br /><searchLink fieldCode="AU" term="%22Denduluri+N%22">Denduluri N</searchLink>; Virginia Cancer Specialists, Arlington, VA, USA.<br /><searchLink fieldCode="AU" term="%22Šeparović+R%22">Šeparović R</searchLink>; University Hospital for Tumors, University Hospital Center 'Sestre milosrdnice', Zagreb, Croatia.<br /><searchLink fieldCode="AU" term="%22Gokmen+E%22">Gokmen E</searchLink>; Ege University Faculty of Medicine, Izmir, Turkey.<br /><searchLink fieldCode="AU" term="%22Bashford+A%22">Bashford A</searchLink>; Auckland Hospital, Auckland, New Zealand.<br /><searchLink fieldCode="AU" term="%22Ruiz+Borrego+M%22">Ruiz Borrego M</searchLink>; Oncology Department, Hospital Universitario Virgen del Rocio, Seville, Spain.<br /><searchLink fieldCode="AU" term="%22Kim+SB%22">Kim SB</searchLink>; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Jakobsen+EH%22">Jakobsen EH</searchLink>; Department of Oncology, Lillebaelt Hospital, Vejle, Denmark.<br /><searchLink fieldCode="AU" term="%22Ciceniene+A%22">Ciceniene A</searchLink>; Oncology Institute of Vilnius University, Vilnius, Lithuania.<br /><searchLink fieldCode="AU" term="%22Inoue+K%22">Inoue K</searchLink>; Breast Oncology, Saitama Cancer Center, Kita-Adachi, Japan.<br /><searchLink fieldCode="AU" term="%22Overkamp+F%22">Overkamp F</searchLink>; Oncologianova GmbH, Recklinghausen, Germany.<br /><searchLink fieldCode="AU" term="%22Heijns+JB%22">Heijns JB</searchLink>; Department of Medical Oncology, Amphia Hospital, Breda, Netherlands.<br /><searchLink fieldCode="AU" term="%22Armstrong+AC%22">Armstrong AC</searchLink>; Department of Oncology, Christie Hospital Manchester, Manchester, UK.<br /><searchLink fieldCode="AU" term="%22Link+JS%22">Link JS</searchLink>; Breastlink Medical Group Inc, Santa Ana, CA, USA.<br /><searchLink fieldCode="AU" term="%22Joy+AA%22">Joy AA</searchLink>; University of Alberta, Department of Oncology, Cross Cancer Institute, Edmonton, AB, Canada.<br /><searchLink fieldCode="AU" term="%22Bryce+R%22">Bryce R</searchLink>; Puma Biotechnology Inc, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Wong+A%22">Wong A</searchLink>; Puma Biotechnology Inc, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Moran+S%22">Moran S</searchLink>; Puma Biotechnology Inc, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Yao+B%22">Yao B</searchLink>; Puma Biotechnology Inc, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Xu+F%22">Xu F</searchLink>; Puma Biotechnology Inc, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Auerbach+A%22">Auerbach A</searchLink>; Puma Biotechnology Inc, Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Buyse+M%22">Buyse M</searchLink>; International Drug Development Institute, Louvain-la-Neuve, Belgium.<br /><searchLink fieldCode="AU" term="%22Chan+A%22">Chan A</searchLink>; Breast Cancer Research Centre-Western Australia, Perth, WA, Australia; Curtin University, Perth, WA, Australia.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22ExteNET+Study+Group%22">ExteNET Study Group</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100957246%22">The Lancet. Oncology</searchLink> [Lancet Oncol] 2017 Dec; Vol. 18 (12), pp. 1688-1700. <i>Date of Electronic Publication: </i>2017 Nov 13.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lancet+Pub%2E+Group%22">Lancet Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100957246 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-5488 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214702045%22">14702045 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=29146401
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S1470-2045(17)30717-9
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1688
    Titles:
      – TitleFull: Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Martin M
      – PersonEntity:
          Name:
            NameFull: Holmes FA
      – PersonEntity:
          Name:
            NameFull: Ejlertsen B
      – PersonEntity:
          Name:
            NameFull: Delaloge S
      – PersonEntity:
          Name:
            NameFull: Moy B
      – PersonEntity:
          Name:
            NameFull: Iwata H
      – PersonEntity:
          Name:
            NameFull: von Minckwitz G
      – PersonEntity:
          Name:
            NameFull: Chia SKL
      – PersonEntity:
          Name:
            NameFull: Mansi J
      – PersonEntity:
          Name:
            NameFull: Barrios CH
      – PersonEntity:
          Name:
            NameFull: Gnant M
      – PersonEntity:
          Name:
            NameFull: Tomašević Z
      – PersonEntity:
          Name:
            NameFull: Denduluri N
      – PersonEntity:
          Name:
            NameFull: Šeparović R
      – PersonEntity:
          Name:
            NameFull: Gokmen E
      – PersonEntity:
          Name:
            NameFull: Bashford A
      – PersonEntity:
          Name:
            NameFull: Ruiz Borrego M
      – PersonEntity:
          Name:
            NameFull: Kim SB
      – PersonEntity:
          Name:
            NameFull: Jakobsen EH
      – PersonEntity:
          Name:
            NameFull: Ciceniene A
      – PersonEntity:
          Name:
            NameFull: Inoue K
      – PersonEntity:
          Name:
            NameFull: Overkamp F
      – PersonEntity:
          Name:
            NameFull: Heijns JB
      – PersonEntity:
          Name:
            NameFull: Armstrong AC
      – PersonEntity:
          Name:
            NameFull: Link JS
      – PersonEntity:
          Name:
            NameFull: Joy AA
      – PersonEntity:
          Name:
            NameFull: Bryce R
      – PersonEntity:
          Name:
            NameFull: Wong A
      – PersonEntity:
          Name:
            NameFull: Moran S
      – PersonEntity:
          Name:
            NameFull: Yao B
      – PersonEntity:
          Name:
            NameFull: Xu F
      – PersonEntity:
          Name:
            NameFull: Auerbach A
      – PersonEntity:
          Name:
            NameFull: Buyse M
      – PersonEntity:
          Name:
            NameFull: Chan A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2017 Dec
              Type: published
              Y: 2017
          Identifiers:
            – Type: issn-electronic
              Value: 1474-5488
          Numbering:
            – Type: volume
              Value: 18
            – Type: issue
              Value: 12
          Titles:
            – TitleFull: The Lancet. Oncology
              Type: main
ResultId 1